<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370379</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI302A102</org_study_id>
    <nct_id>NCT04370379</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients</brief_title>
  <official_title>A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI302 in Patients With Neovascular Age-related Macular Degeneration (nAMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed for multi-center, open-label, randomized, dose escalation phase I
      trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of
      IBI302 in neovascular AMD patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular safety, assessed by BCVA, slitlamp examination, ophthalmoscopy, IOP, fundus photography</measure>
    <time_frame>Baseline to Day140</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Baseline to Day140</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in central subfield thickness by OCT compared with baseline</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CNV characteristics and CNV area by FA compared with baseline</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BCVA compared with baseline</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of anti-drug antibody and neutralizing antibody of IBI302</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the area under the drug-time curve from 0 to time t of IBI302</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the area under the curve at the time of 0-infinity of IBI302</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The peak concentration of IBI302</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The peak time of IBI302</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance rate of IBI302</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of IBI302</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF concentration</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of complement fragments</measure>
    <time_frame>Baseline to Day140</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>low dose of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2mg aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI302 (the first dose level)</intervention_name>
    <description>q4week (3 injections) followed by PRN dosing</description>
    <arm_group_label>low dose of IBI302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI302 (the second dose level)</intervention_name>
    <description>q4week (3 injections) followed by PRN dosing</description>
    <arm_group_label>high dose of IBI302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>2mg, q4week (3 injections) followed by q8week</description>
    <arm_group_label>2mg aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria

          1. Male or female patient ≥ 50 yrs. of age.

          2. Active subfoveal or parafoveal CNV secondary to neovascular AMD.

          3. Willing and able to sign informed consent form and comply with visit and study
             procedures per protocol.

        Exclusion criteria

          1. Presence of uncontrolled glaucoma in the study eye (defined as IOP≥30mmHg despite the
             standardized treatment);

          2. Presence of active intraocular or periocular inflammation or infection;

          3. History of severe hypersensitivity/allergy to active ingredients or any excipients of
             the study drug, or fluorescein and povidone iodine;

          4. Participated in any clinical study of any other drug within three months prior to
             enrollment, or attempted to participate in other drug trials during the study;

          5. Diabetic patients have any of the following conditions:HbA1c&gt;7.5% when screening;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Sun, PI</last_name>
      <phone>021-36216424</phone>
      <phone_ext>6423</phone_ext>
      <email>xdsun@sjtu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

